| 开盘价:-- | 最高价:-- | 最低价:-- | 52周最高价:-- | 52周最低价:-- |
| 成交量:-- | 平均成交量:-- | 市值:-- | 市盈率:-- | 预期市盈率:-- |
| 每股收益:-- | 贝塔系数:-- | 股息:-- | 收益率:-- | 总股本:-- |
| 证券代码:akba | 公司名称:Akebia Therapeutics, Inc. | 公司中文简称: |
| 公司简介： Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. |
||
| 公司网站： http://www.akebia.com |
||
| 公司地址： 245 First Street Suite 1400 Cambridge |
||